Is Addition of GNRH Agonist to HRT Significant in Improving The Outcome in FTE Transfer Cycles : Randomized Study

Khalid M. Salama, Ibrahim I. Souidan

Department of Obstetrics and Gynecology, Faculty of Medicine, Benha University, Egypt

ABSTRACT

Background: Despite the high number of frozen embryo transfer cycles being conducted, there is much debate about which protocol for endometrial preparation is ideal.

Aim: The aim of this study is detect the value of gonadotropin-releasing hormone agonist (GNRH-a) in the preparation of the endometrium regarding the cycle outcome.

Materials and Methods: One hundred forty women participated in the study. They were randomly divided into two groups; group 1 and group 2. The patients of group 1 received injection of GnRH-a triptoreline (3.75 mg) on the day-21 of the menstrual cycle proceeding the replacement cycle. Both groups received exogenous estradiol starting from the second day of the cycle then the dose was increased incrementally till the endometrial thickness was ≥ 8mm or more. Progesterone was given to the patients before embryo transfer and continued thereafter. Twelve days later, serum pregnancy test was done and if positive, transvaginal ultrasonography was done two weeks later for detection of embryo cardiac activity.

Results: Both groups showed no statistically significant differences regarding demographic, clinical and laboratory data and their relations to pregnancy. Serum pregnancy tests detected chemical pregnancy that was confirmed by transvaginal ultrasonography at 6 weeks gestation in only 49.3% of women (clinical pregnancy rate =49.3%). Only six women aborted at 8-12 weeks gestation (ongoing pregnancy rate =45%). There were no significant differences between both groups regarding the clinical outcome.

Conclusion: Addition of GNRH-a to HRT to prepare the endometrium in the FTE transfer cycle had no significant effect on the clinical outcome.

Key Words: FTE transfer, GNRH, HRT

INTRODUCTION

Successful implantation depends on synchronicity between the developmental stage of the embryo and the prepared endometrium[1].

The procedure of freezing and thawing is used for storage of embryos and their transfer in non-hyper stimulated cycle. The improvement of laboratory conditions led to progressive increase of FTE transfer cycles[2]. Furthermore, the pregnancy rate in FTE transfer is more than following fresh ET[3, 4].

Various protocols of endometrial preparation have been described. They included pure natural cycle (NC), with detection of LH in blood or urine, natural modified cycle (nMC) in which HCG is administered, artificial cycle with estradiol (E2) and progesterone (p4) with or without addition of gonadotropin releasing hormone agonist (GNRH-a) and lastly low doses of gonadotropins. However, there is still a debate which protocol is ideal[5].

Each of these methods has advantages and disadvantages. Natural cycles allow the women to transfer without treatment, but its problem is scheduling the patient’s activity in an IVF unit because the date of transfer is dictated by the patient’s ovulation and this method cannot be offered to women with irregular cycles. Artificial cycles resolved these two problems and are the most commonly used approach worldwide. Stimulated cycles are associated with higher cost, risk of side effects of the treatment. In spite of this discrepancy, the pregnancy and live birth rates were comparable in all methods[6].

Currently most IVF units use GNRH-a in the artificial preparations of the endometrium to induce pituitary down
regulation to prevent spontaneous ovulation. However, this method is costly and has the risk of the hypo estrogenic state that may lengthen the preparation of the endometrium. All recent studies compared the artificial preparation with or without pituitary suppression and found no significant differences[7]. The optimal protocol is the most efficient and cost effective and associated with the lowest burden on the patients[8].

AIM OF THE WORK

The aim of this study is to detect the value of addition of GnRH-a in the artificial preparation of the endometrium regarding the cycle outcome.

PATIENTS AND METHODS

Patient data: This randomized study was conducted at Dar El-Teb Hospital, Dokki, Giza, Egypt, during the period from December 2017 till October 2019. Approval of the Local Ethical Committee was obtained from all participants in the study. One hundred forty women participated in the study with the following criteria; age (22-40 years) and BMI (less than 36kg/m2).

Exclusion criteria: Gross uterine and tubal pathology, endometrial thickness ≤ 7 mm at the time of embryo transfer, poor quality of embryos after thawing, and refusal to participate in the study at any step of the cycle.

Randomization and Grouping: Randomization of all the women was conducted by using sealed envelopes that contain cards prepared by a blinded assistant and cards were chosen by the patient herself. They were divided into two groups (group 1 and group 2). The patients of group 1 received injection of GnRH-a triptoreline (Decapeptyl, Ferring Pharmaceuticals Ltd., Wittland, Germany; 3.75 mg, subcutaneous injection) on the day-21 of the menstrual cycle preceding the replacement cycle.

Study protocol: The classic slow freezing and rapid thawing protocol of Testart[6,10] was applied using a programmable freezer (Planer; Middlesex, UK) and embryo freezing and thawing kits (Irvine Scientific, Santa Ana, CA, USA) were used. After thawing, all embryos were transferred to culture in vitro for 2 days[11]. On the third day, embryos in G1 and G2 grade were defined as good quality embryos and 1-3 embryos of good quality were transferred, while poorer grade embryos were discarded[12].

All women received the same hormone replacement therapy in the form of estradiol valerate (Progynova 2 mg, Bayer Schering Pharma, UK). The estradiol was started on day-2 of menses of replacement cycle as a daily dose of 2 mg and the doses were increased incrementally till endometrial thickness was at least 8 mm. Endometrial thickness was detected by transvaginal ultrasound (Sonoline Prima 7.5 MHz, Siemens). Then, oral micronized progesterone (300 mg per day (progester, micronized progesterone 100 mg, Technopharma, Egypt, for pharco pharmaceuticals, Amriya, Alexandria) was given for two days before cleaved embryos transfer and for four days before blastocyst transfer and continued thereafter. Twelve days later to embryo transfer, serum pregnancy test was done and if positive, the clinical pregnancy was confirmed by TVS for detection of gestational sacs and embryo cardiac activity. Antenatal care of the pregnancy was done elsewhere because our unit is specialized for IVF only.

Primary outcome: The clinical pregnancy was detected by TVS at 6 weeks gestation (gestational sacs and embryo cardiac activity). The ongoing pregnancy was detected by abdominal ultrasound at 12 weeks. Detection of chemical pregnancy that was defined as a positive pregnancy test but the pregnancy did not appear on ultrasound examination.

Sample size estimation: The sample size was calculated using Open Epi according to the following; the percentage of pregnancy among GnRH group was 65.5% and among HRT group was 42%[13] so, at power of study 80% and CI 95%. The sample size was calculated to be 140 cases divided into two equal groups.

STATISTICAL ANALYSIS:

The collected data were computerized and statistically analyzed using SPSS program (Statistical Package for Social Science) version 25.0. Qualitative data were represented as frequencies and relative percentages. Chi square test was used to calculate difference between qualitative variables. Quantitative data were expressed as mean ± SD (Standard deviation). Independent T test and Mann Whitney test was used to calculate the difference between quantitative variables. The threshold of significance is fixed at 5% level (P-value), P value of > 0.05 indicates non-significant results, P value of < 0.05 indicates significant results and P value of < 0.01 indicates highly significant results.

RESULTS

From 146 women consented to participate in the study, 6 women were excluded from the work; 2 women were having poor endometrial thickness, 2 women were having embryos of poor quality, and the remaining 2 women refused to participate in the study (Fig.1).
Only one hundred forty women completed the study. Both groups showed no statistically significant differences regarding demographic, clinical and laboratory data and their relations to pregnancy (Table 1).

After thawing, assessment of embryos for transfer was done, 244 embryos were transferred to all women with a mean number 1.74 embryo per woman.

Serum pregnancy tests detected chemical pregnancy that was confirmed by TVS at 6 weeks gestation in only 49.3% of women (clinical pregnancy rate =49.3%). Only six women aborted at 8-12 weeks gestation (ongoing pregnancy rate=45%). There were no significant differences between both groups regarding the clinical outcome (Table 2).

Fig. 1: Consort flow diagram
Table 1: Shows demographic, clinical and laboratory data and their relations to pregnancy

<table>
<thead>
<tr>
<th>Variable</th>
<th>HRT+GNRH (n=70)</th>
<th>HRT (n=70)</th>
<th>Test</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30.33 ± 5.65</td>
<td>30.79 ± 6.16</td>
<td>t</td>
<td>0.65</td>
<td>NS</td>
</tr>
<tr>
<td>22 - 40</td>
<td>22 - 40</td>
<td>0.46</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMI (Kg/m²)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30.41 ± 23.20</td>
<td>31.2 ± 2.91</td>
<td>t</td>
<td>0.13</td>
<td>NS</td>
</tr>
<tr>
<td>26 - 36</td>
<td>26 - 36</td>
<td>1.52</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cause of infertility:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male factor</td>
<td>16 (22.9%)</td>
<td>19 (27.1%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tubal</td>
<td>16 (22.9%)</td>
<td>22 (31.4%)</td>
<td>χ²</td>
<td>0.12</td>
</tr>
<tr>
<td>17 (24%)</td>
<td>5.80</td>
<td>NS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreased ovarian reserve</td>
<td>28 (40%)</td>
<td>15 (21.4%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCO</td>
<td>10 (14.3%)</td>
<td>14 (20%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Previous fresh cycles</td>
<td>59 (84.3%)</td>
<td>63 (90%)</td>
<td>χ²</td>
<td>0.31</td>
</tr>
<tr>
<td>8 - 12</td>
<td>1.02</td>
<td>NS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Previous FET cycles</td>
<td>10 (14.3%)</td>
<td>12 (17.1%)</td>
<td>χ²</td>
<td>0.64</td>
</tr>
<tr>
<td>Endometrial thickness</td>
<td>9.81 ± 1.40</td>
<td>9.64 ± 1.30</td>
<td>t</td>
<td>0.45</td>
</tr>
<tr>
<td>8 - 12</td>
<td>0.75</td>
<td>NS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duration of cryopreservation(month)</td>
<td>17.99 ± 10.20</td>
<td>20.61 ± 9.67</td>
<td>MW</td>
<td>0.29</td>
</tr>
<tr>
<td>5 - 36</td>
<td>1.05</td>
<td>NS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Developmental stage of cryo preserved embryo</td>
<td>(n=117)</td>
<td>(n=127)</td>
<td>χ²</td>
<td>0.07</td>
</tr>
<tr>
<td>cleaved embryo</td>
<td>50 (42.7%)</td>
<td>69 (54.3%)</td>
<td></td>
<td>NS</td>
</tr>
<tr>
<td>Blastocyst</td>
<td>67 (57.3%)</td>
<td>58 (45.7%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Data are presented as mean±SD, median and ranges are in parenthesis; *: Significant (p<0.05); **: Highly Significant (p<0.01).
Table 2: Shows outcome among the studied group

<table>
<thead>
<tr>
<th>Variable</th>
<th>HRT+GNRH (n=70 woman)</th>
<th>HRT (n=70 woman)</th>
<th>Test</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total NO of transferred embryos(TTE):</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>38 (54.3%)</td>
<td>32 (45.8%)</td>
<td>χ²</td>
<td>0.58</td>
</tr>
<tr>
<td>2</td>
<td>17 (24.3%)</td>
<td>19 (27.1%)</td>
<td>1.10</td>
<td>NS</td>
</tr>
<tr>
<td>3</td>
<td>15 (21.4%)</td>
<td>19 (27.1%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean NO of transferred embryos</td>
<td>1.67 ± 0.81</td>
<td>1.81 ± 0.84</td>
<td>MW=1.04</td>
<td>0.30</td>
</tr>
<tr>
<td>Chemical pregnancy</td>
<td>38 (54.3%)</td>
<td>44 (62.9%)</td>
<td>χ²=1.06</td>
<td>0.30</td>
</tr>
<tr>
<td>Clinical pregnancy</td>
<td>32 (45.7%)</td>
<td>37 (52.9%)</td>
<td>χ²=0.71</td>
<td>0.40</td>
</tr>
<tr>
<td>Ongoing pregnancy</td>
<td>32 (45.7%)</td>
<td>31 (44.3%)</td>
<td>χ²=0.03</td>
<td>0.87</td>
</tr>
<tr>
<td>No of gestational sacs(IR):</td>
<td>(n=32)</td>
<td>(n=37)</td>
<td>χ²</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>10 (68.8%)</td>
<td>9 (24.3%)</td>
<td>0.41</td>
<td>0.52</td>
</tr>
<tr>
<td>2</td>
<td>22 (31.3%)</td>
<td>28 (75.7%)</td>
<td>0.62</td>
<td>0.43</td>
</tr>
<tr>
<td>IR</td>
<td>54/117=46%</td>
<td>65/127=51%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Data are presented as mean±SD, median and ranges are in parenthesis; *: Significant (p<0.05); **: Highly Significant (p<0.01).
DISCUSSION

The implantation of the embryo in FTE transfer depends on the synchronization between the prepared endometrium and developed embryo. The endometrial preparation may be artificially induced using exogenous estrogen with or without GNRH agonist[14]. This study compared this artificial endometrial preparation with or without previous pituitary down regulation. We found no significant differences between both methods regarding implantation, chemical, clinical and ongoing pregnancy rates.

Different methods were used to prepare the endometrium. The originally used methods were NC and nMC, but due to complicated follow up (blood tests and serial US scans), artificial preparation by exogenous estrogen was introduced. Others added GnRH a in an attempt to confirm non ovulation to improve the outcome, but no significant differences were detected[44].

The transfer of frozen embryo must synchronize the ovulation in NC or after preparing the endometrium by E-P. The exogenous hormonal regimens improved the outcome when compared to NC but this improvement was not significant[15].

Several studies either randomized or retrospective tried to compare both regimens of artificial preparation and found no significant differences between addition of GnRH and non-addition to exogenous steroids regarding the cycle outcome[10].

Different doses and method of administration of exogenous steroids were used. In a study of Simon et al.[17], they used fixed daily doses of estradiol (6 mg) to women not receiving GnRH-a; while the women who received GnRH-a were taken 4 mg of estradiol. Also, they used micronized progesterone tablets 300 mg three times vaginally. Other study used transdermal estrogen patch in a fixed dose with or without previous down regulation. In our study, we used incrementally increased doses of estrogen and oral micronized progesterone tablets 300 mg daily. The results were similar to those reported by Simon et al.[17] and Dal Prato et al.[18].

In this study, we started the estrogen in a low dose then increased gradually; while Simon et al.[17] started by a high fixed dose 6 mg whereas Pattinson et al.[19] started from the second to fifth day of the cycle and maintained by low fixed doses 2 mg.

Non-physiological high estradiol levels in artificial cycle was claimed to cause endometrial damage and variations in the implantation window[20]. If the claim was taken into account, lower pregnancy rates would be expected.

Hill et al. believed that without the use of GNRH agonist, early endometrial preparation with estrogen at 1-2 of the menstruation was sufficient for suppression of ovulation and when given in step up manner not fixed was more physiologic and was more sufficient for endometrial maturation and subsequently embryo implantation.

Glujovsky et al.[21] believed that the appearance of dominant follicle did not affect the outcome of FTE transfer cycles when the endometrium was prepared without previous down regulation.

Zhihong et al.[22] believed that the endometrium to be receptive needs thick endometrium 5-8 mm for optimal development of progesterone receptors and endometrial transformation. Also, they stated that without the use of GnRH agonist only the US scan not E2 level on progesterone initial day can help to predict the cycle outcome.

Pretreatment with GnRH-a had the advantage of inhibition of spontaneous ovulation and cancellation of the cycle. But many studies compared artificial endometrial preparation with and without GnRH-a and found no significant difference on the cycle outcome[22, 23, 14].

Some studies used different forms of GnRH-a and found no significant difference on the cycle outcome[25, 18].

Kalem, et al.[24] concluded that early luteinization may exist in 5% and complete down regulation with GnRH-a cannot be guaranteed in artificial cycles. The only detected positive factor affecting the pregnancy rate was the endometrial thickness which was determined by estrogen[25, 26, 27].

Previous studies concluded that the previous down regulation was not needed for endometrial preparation in FTE transfer cycle[17, 28].

Programmed cycle without GnRH-a pretreatment was more convenient to the patient and medical staff and resulted in the same outcome at a lower cost. The woman still had the option of choosing the desired cycle to transfer and the used medication was more comfortable[23]. In clear, the program without GnRH-a may be preferred because it was simple and of low cost especially in developing countries.

CONCLUSION

Addition of GnRH-a to HRT to prepare the endometrium in the FTE transfer cycle had no significant effect on the clinical outcome.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE
The study was approved by the Local Ethical Committee of Benha University Hospital and the reference number is not applicable. Written informed consent was obtained from each participant before the study.

CONFLICT OF INTEREST

There are no conflicts of interests.

REFERENCES


